Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLGA: Capecitabine and Bevacizumab with Radiotherapy for Oligometastatic Colorectal Cancer
NCT01759238Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- May 2013
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, bevacizumab in colorectal cancer (CRC), sponsored by University Medical Center Hamburg-Eppendorf. Started May 2013; status: terminated.
02
Drugs
capecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01759238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01759238.